HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Vigonvita Life Sciences - The Challenges Behind the Pipeline and the Outlook

Pre-IPO Softcare - Strong Performance Growth Momentum Would Continue

Pre-IPO Muyuan Foods - The Hog King in China Has Greater Potential and Resilience

A Rare Surge in China's Stock Market - But, This Is Not a Bull Market

Pre-IPO Midea Group H Share - Here Are the Risks Behind

Pre-IPO Sichuan Biokin Pharmaceutical - Would Investors Be Willing to Take a Gamble?

Equity Capital Markets

Zephyrm Bioscience / Equity Capital Markets

<ul>
<li>There’s great potential for PSCs, which provides new treatment options for complex diseases where traditional therapies are ineffective.The more solid the platform technology, the greater the dividends in later stage.</li>
<li>Zephyrm's pipeline candidates are promising. However, considering the R&amp;D risks, the uncertainty of future commercialization and product safety profile, we think the investment risk of this Company is relatively high.</li>
<li>Valuation of overseas peers is not high. In our view, valuation performance of Zephyrm would be largely depend on its clinical results of pipeline, which is a gamble for investors.</li>
</ul>


There’s great potential for PSCs, which provides new treatment options for complex diseases where traditional therapies are ineffective.The more solid the platform technology, the greater the dividends in later stage.
Zephyrm's pipeline candidates are promising. However, considering the R&amp;D risks, the uncertainty of future commercialization and product safety profile, we think the investment risk of this Company is relatively high.
Valuation of overseas peers is not high. In our view, valuation performance of Zephyrm would be largely depend on its clinical results of pipeline, which is a gamble for investors.


Pre-IPO Zephyrm Bioscience - Despite Promising Pipeline, Investment Risk Is High